Premium
Pre‐operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU 486)
Author(s) -
HENSHAW R. C.,
TEMPLETON A. A.
Publication year - 1991
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1991.tb15341.x
Subject(s) - medicine , mifepristone , pessary , vacuum aspiration , placebo , cervix , adverse effect , randomized controlled trial , obstetrics , pregnancy , gynecology , surgery , population , family planning , genetics , alternative medicine , environmental health , pathology , cancer , research methodology , biology
Objective— To compare the effectiveness of 200 mg mifepristone with 1 mg gcmeprost vaginal pessary in achieving cervical dilatation and softening (‘priming’) before late first trimester pregnancy vacuum aspiration. Design— A randomized, operator blind, placebo controlled trial. Setting— UK teaching hospital. Subjects— 90 primigravid women with 63–91 days amenorrhoea and ultrasonically confirmed single living fetus of correct size for gestational age. Interventions— The women were allocated to receive 200 mg mifepristone orally or an identical oral placebo 36 h before operation or 1 mg gemeprost vaginal pessary 3–4 h preoperatively. Main outcome measures— Onset of new symptoms following drug administration, a proven objective measure of the force required to dilate the cervix, and estimated intraoperative blood loss. Results— There were no significant diffcrences in the baseline cervical dilatation, the force required to dilate the cervix or the volume of intraoperative blood loss between the active treatment groups. Both drugs were significantly more effective than placebo. Significantly fewer women in the mifepristone group had adverse side effects than in the gemeprost group. Conclusions— Mifepristone is a highly effective cervical priming agent, and has the advantages of being an oral prcparation associated with few side effects.